Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12225835 | 0.90 | KDM5A (0.46) | DNM1LMNAMEN1KMT2AKDM5A | |
| SCHEMBL421389 | 0.87 | KDM5A (0.38) | DNM1LMNAMEN1KMT2AKDM5A | |
| SCHEMBL16994180 | 0.86 | DNM1 (0.42) | DNM1LMNAMEN1KMT2ANLRP3 | |
| SCHEMBL12225833 | 0.82 | LMNA (0.38) | DNM1LMNAMEN1KMT2AKDM5A | |
| SCHEMBL10030578 | 0.82 | DNM1 (0.56) | DNM1MEN1KMT2AKDM5ALTA4H | |
| SCHEMBL420322 | 0.81 | LMNA (0.53) | LMNANLRP3LPAR1LPAR3ENPP2 | |
| SCHEMBL8335902 | 0.81 | LMNA (0.53) | LMNANLRP3LPAR1LPAR3ENPP2 | |
| SCHEMBL12009417 | 0.81 | LMNA (0.39) | LMNAALDH1A1 | |
| SCHEMBL419297 | 0.80 | ALDH1A1 (0.38) | LMNAMEN1KMT2AALDH1A1POLB | |
| SCHEMBL421688 | 0.80 | LMNA (0.36) | DNM1LMNAMEN1KMT2ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700627-B2 | Biodegradable poly (beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160022821-A1 | BIODEGRADABLE POLY (BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-28 | — | — | US | disclosed |
| US-8557231-B2 | Biodegradable poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-15 | — | — | US | disclosed |
| US-8287849-B2 | Biodegradable poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-16 | — | — | US | disclosed |
| US-RE43612-E1 | Biodegradable poly(β-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120065358-A1 | BIODEGRADABLE POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257249-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| US-8003621-B2 | Drug carriers | NITTO DENKO CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7943179-B2 | Drug delivery particle; useful in genetic vaccination; eg poly(beta-amino esters) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | TZIANABOS ARTHUR | 2011-03-10 | — | — | US | disclosed |
| US-20100036084-A1 | BIODEGRADABLE POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090105179-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-7427394-B2 | Delivering labile agents; buffering effect; transfecting nucleic acids; nontoxic | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257249-A1 | DRUG CARRIERS | HDGF, FIBP, SLC47A2 | DNM1 2090/4885LMNA 1660/4885MEN1 2244/4885 |
| US-20160022821-A1 | BIODEGRADABLE POLY (BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, NPEPPS | DNM1 3167/4885LMNA 81/4885MEN1 1738/4885 |
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, ACP1, TUBB3 | DNM1 2962/4885LMNA 687/4885MEN1 1098/4885 |
| US-20090105179-A1 | DRUG CARRIERS | HDGF, FIBP, SLC47A2 | DNM1 2090/4885LMNA 1660/4885MEN1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.